Reckitt Benckiser Group plc (OTCMKTS:RBGLY - Get Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $12.70 and traded as low as $12.41. Reckitt Benckiser Group shares last traded at $12.59, with a volume of 320,171 shares traded.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on RBGLY shares. Barclays downgraded Reckitt Benckiser Group from an "overweight" rating to an "equal weight" rating in a report on Tuesday, February 4th. Royal Bank of Canada reissued an "outperform" rating on shares of Reckitt Benckiser Group in a research report on Friday, March 7th. Three analysts have rated the stock with a hold rating, two have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy".
Get Our Latest Analysis on Reckitt Benckiser Group
Reckitt Benckiser Group Price Performance
The firm's fifty day simple moving average is $13.18 and its 200-day simple moving average is $12.71. The company has a quick ratio of 0.47, a current ratio of 0.69 and a debt-to-equity ratio of 0.97.
Reckitt Benckiser Group Increases Dividend
The company also recently disclosed a dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 11th will be issued a $0.2909 dividend. This is a positive change from Reckitt Benckiser Group's previous dividend of $0.19. The ex-dividend date of this dividend is Friday, April 11th.
About Reckitt Benckiser Group
(
Get Free Report)
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.
Further Reading
Before you consider Reckitt Benckiser Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reckitt Benckiser Group wasn't on the list.
While Reckitt Benckiser Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
